MALVERN, Pa.–(BUSINESS WIRE)–#Enterobacteriaceae—VenatoRx
Pharmaceuticals announced that its President and CEO, Christopher
J. Burns, Ph.D., will present at the UBS
Global Healthcare Conference on Monday, May 21, 2018 at 8:00am ET in
Ballroom V at the Grand Hyatt New York. The presentation will be webcast
Dr. Burns will present attendees with an overview of VenatoRx’s pipeline
and its unique operating model of leveraging non-dilutive funding to
maximize investor dollars.
About VenatoRx Pharmaceuticals, Inc.
Led by a world-class team of pharmaceutical veterans, VenatoRx is a
private pharmaceutical company that is developing a new wave of
antibiotic products to combat the increasing threat of carbapenem
antibiotic resistance. VenatoRx’s lead product, VNRX-5133, is an
injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly
inhibits all four Ambler classes of beta-lactamases. Early clinical
studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to
start Phase 3 pivotal trials in the second half of 2018. In addition,
VenatoRx has a broad pipeline of preclinical programs, including a
broad-spectrum orally bioavailable BLI, and a novel class of
Penicillin-Binding Protein (PBP) inhibitors that are impervious to
beta-lactamase-driven resistance. For more information, please visit www.venatorx.com.
VenatoRx Pharmaceuticals, Inc.
Heather Hunter, 610-644-8935